Healthcare provider profile · identity verified

Donna Jean Dolan, MD

Internal Medicine · SAN MARCOS, TX · NPI 1831134824

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	544	134
Rosuvastatin Calcium	Rosuvastatin Calcium	342	96
Amlodipine Besylate	Amlodipine Besylate	322	101
Atorvastatin Calcium	Atorvastatin Calcium	306	92
Losartan Potassium	Losartan Potassium	300	82
Lisinopril	Lisinopril	276	74
Hydrochlorothiazide	Hydrochlorothiazide	189	53
Omeprazole	Omeprazole	168	54
Escitalopram Oxalate	Escitalopram Oxalate	143	43
Metformin Hcl Er	Metformin Hcl	140	41
Lovastatin	Lovastatin	126	33
Metformin Hcl	Metformin Hcl	117	30
Sertraline Hcl	Sertraline Hcl	116	28
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	109	28
Gabapentin	Gabapentin	107	30
Trazodone Hcl	Trazodone Hcl	105	26
Pantoprazole Sodium	Pantoprazole Sodium	95	28
Glipizide Er	Glipizide	86	25
Jardiance	Empagliflozin	85	20
Metoprolol Succinate	Metoprolol Succinate	81	23
Simvastatin	Simvastatin	81	23
Fluticasone Propionate	Fluticasone Propionate	79	23
Synthroid	Levothyroxine Sodium	79	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	76	21
Meloxicam	Meloxicam	76	16
Pravastatin Sodium	Pravastatin Sodium	75	20
Alendronate Sodium	Alendronate Sodium	74	24
Bupropion Xl	Bupropion Hcl	65	16
Duloxetine Hcl	Duloxetine Hcl	65	17
Famotidine	Famotidine	61	16
Alprazolam	Alprazolam	57	17
Montelukast Sodium	Montelukast Sodium	54	18
Ozempic	Semaglutide	54	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	54	13
Triamcinolone Acetonide	Triamcinolone Acetonide	52	28
Citalopram Hbr	Citalopram Hydrobromide	46	11
Venlafaxine Hcl Er	Venlafaxine Hcl	46	12
Allopurinol	Allopurinol	43	11
Albuterol Sulfate Hfa	Albuterol Sulfate	42	15
Ezetimibe	Ezetimibe	42	13
Furosemide	Furosemide	41	14
Tramadol Hcl	Tramadol Hcl	41	16
Cephalexin	Cephalexin	40	35
Glimepiride	Glimepiride	40	11
Metoprolol Tartrate	Metoprolol Tartrate	40	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	39	suppressed
Valacyclovir	Valacyclovir Hcl	39	16
Mounjaro	Tirzepatide	37	suppressed
Potassium Chloride	Potassium Chloride	37	13
Prednisone	Prednisone	36	22
Carvedilol	Carvedilol	35	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Solifenacin Succinate	Solifenacin Succinate	35	11
Tizanidine Hcl	Tizanidine Hcl	33	15
Clonazepam	Clonazepam	30	suppressed
Donepezil Hcl	Donepezil Hcl	30	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	29	suppressed
Paroxetine Hcl	Paroxetine Hcl	29	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	28	suppressed
Trulicity	Dulaglutide	27	suppressed
Glipizide	Glipizide	26	suppressed
Lorazepam	Lorazepam	26	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	25	suppressed
Raloxifene Hcl	Raloxifene Hcl	25	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	25	suppressed
Atenolol	Atenolol	23	suppressed
Euthyrox	Levothyroxine Sodium	23	suppressed
Liothyronine Sodium	Liothyronine Sodium	23	suppressed
Ramipril	Ramipril	23	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	18
Eszopiclone	Eszopiclone	22	suppressed
Farxiga	Dapagliflozin Propanediol	22	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	22	suppressed
Diclofenac Sodium	Diclofenac Sodium	21	11
Benazepril Hcl	Benazepril Hcl	20	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	20	suppressed
Myrbetriq	Mirabegron	20	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	20	suppressed
Warfarin Sodium	Warfarin Sodium	20	suppressed
Azithromycin	Azithromycin	19	16
Celecoxib	Celecoxib	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	19	suppressed
Prolia	Denosumab	19	14
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	19	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	18	suppressed
Nystatin-Triamcinolone	Nystatin/Triamcinolone Acet	17	suppressed
Ropinirole Hcl	Ropinirole Hcl	17	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	11
Doxycycline Hyclate	Doxycycline Hyclate	16	14
Januvia	Sitagliptin Phosphate	16	suppressed
Memantine Hcl	Memantine Hcl	16	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	15	suppressed
Propranolol Hcl Er	Propranolol Hcl	15	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Ondansetron Hcl	Ondansetron Hcl	14	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	14	14
Topiramate	Topiramate	14	suppressed
Valsartan	Valsartan	14	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Pregabalin	Pregabalin	13	suppressed
Verapamil Er	Verapamil Hcl	13	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	12	suppressed
Eliquis	Apixaban	12	suppressed
Felodipine Er	Felodipine	12	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	12	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Divalproex Sodium	Divalproex Sodium	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error